

# CAR T-Cell Therapy for Acute Lymphoblastic Leukemia - Pipeline Insight, 2021

<https://marketpublishers.com/r/CFFDF2D9A754EN.html>

Date: February 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: CFFDF2D9A754EN

## Abstracts

This report can be delivered to the clients within 48-72 Hours

DelveInsight's, "CAR T-Cell Therapy for Acute Lymphoblastic Leukemia - Pipeline Insight, 2021," report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in CAR T-Cell Therapy for Acute Lymphoblastic Leukemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

## Geography Covered

Global coverage

CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Understanding

CAR T-Cell Therapy for Acute Lymphoblastic Leukemia: Overview

Acute Lymphoblastic Leukemia (ALL) also known as acute lymphocytic leukemia is a type of blood cancer that affects the lymphocytes a category of white blood cells and starts in the bone marrow (the soft tissue inside certain bones), the site for hematopoiesis. ALL progress rapidly, invade blood stream and spread to other organs such as liver, spleen, lymph nodes. ALL is prevalent in both children and adults. Exposure to radiations, hazardous chemicals such as benzene, and T-lymphocyte infection can raise the risk for ALL. Chimeric Antigen Receptor (CAR) T- Cell therapy

which make use of reengineered T cells to produce chimeric antigen receptor on cell surface to recognize and attack cancerous cells with specific antigen. This therapy has shown draconian success in the field of anti-tumor immunotherapy specifically for the treatment of B-cell malignancies.

“CAR T-Cell Therapy for Acute Lymphoblastic Leukemia - Pipeline Insight, 2021” report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the CAR T-Cell Therapy for Acute Lymphoblastic Leukemia pipeline landscape is provided which includes the disease overview and CAR T-Cell Therapy for Acute Lymphoblastic Leukemia treatment guidelines. The assessment part of the report embraces, in depth CAR T-Cell Therapy for Acute Lymphoblastic Leukemia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, CAR T-Cell Therapy for Acute Lymphoblastic Leukemia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

## **Report Highlights**

The companies and academics are working to assess challenges and seek opportunities that could influence CAR T-Cell Therapy for Acute Lymphoblastic Leukemia R&D. The therapies under development are focused on novel approaches to treat/improve CAR T-Cell Therapy for Acute Lymphoblastic Leukemia.

### **CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Emerging Drugs Chapters**

This segment of the CAR T-Cell Therapy for Acute Lymphoblastic Leukemia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

### **CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Emerging Drugs**

#### **AUTO 3: Autolus**

AUTO3 is a programmed T cell therapy containing two independent chimeric antigen receptors targeting CD19 and CD22 that have each been independently optimized for

single target activity. The therapy is designed to minimize relapse due to single antigen loss in patients with B cell malignancies and is currently being tested for precursor cell lymphoblastic leukemia-lymphoma in its Phase I/II of clinical trials. The drug has also been designated with orphan drug status for precursor cell lymphoblastic leukemia.

#### PCAR019: PersonGen Biotherapeutics

Persongen's "breakthrough" therapy PCAR019 is currently being evaluated for the treatment of Acute Lymphoblastic Leukemia. The drug is in its phase I trial and targets the CD-19 which is expressed in most B-malignant tumors especially in the former B cells ALL.

Further product details are provided in the report.....

#### CAR T-Cell Therapy for Acute Lymphoblastic Leukemia: Therapeutic Assessment

This segment of the report provides insights about the different CAR T-Cell Therapy for Acute Lymphoblastic Leukemia drugs segregated based on following parameters that define the scope of the report, such as:

#### Major Players in CAR T-Cell Therapy for Acute Lymphoblastic Leukemia

There are approx. 5+ key companies which are developing the therapies for CAR T-Cell Therapy for Acute Lymphoblastic Leukemia. The companies which have their CAR T-Cell Therapy for Acute Lymphoblastic Leukemia drug candidates in the mid to advanced stage, i.e. Phase I/II include, Autolus and others.

#### Phases

DelveInsight's report covers around 5+ products under different phases of clinical development like

Mid-stage products (Phase II and Phase I/II)

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

## **Route of Administration**

CAR T-Cell Therapy for Acute Lymphoblastic Leukemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Subcutaneous

Intravenous

Oral

Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as

Small molecules

Natural metabolites

Monoclonal antibodies

## **Product Type**

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

**CAR T-Cell Therapy for Acute Lymphoblastic Leukemia: Pipeline Development Activities**

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses CAR T-Cell Therapy for Acute Lymphoblastic Leukemia therapeutic drugs key players involved in developing key

drugs.

## **Pipeline Development Activities**

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging CAR T-Cell Therapy for Acute Lymphoblastic Leukemia drugs.

### **CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Report Insights**

CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

### **CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Report Assessment**

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

## **Key Questions**

Current Treatment Scenario and Emerging Therapies:

How many companies are developing CAR T-Cell Therapy for Acute Lymphoblastic Leukemia drugs?

How many CAR T-Cell Therapy for Acute Lymphoblastic Leukemia drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of CAR T-Cell Therapy for Acute Lymphoblastic Leukemia?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the CAR T-Cell Therapy for Acute Lymphoblastic Leukemia therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for CAR T-Cell Therapy for Acute Lymphoblastic Leukemia and their status?

What are the key designations that have been granted to the emerging drugs?

## **Key Players**

Autolus

PersonGen Biotherapeutics

Pepromene Bio, Inc.

Actinium Pharmaceuticals

## **Key Products**

AUTO 3

PCAR019

BAFF-R-CAR-T

Apamistamab



## Contents

Introduction

Executive Summary

CAR T-Cell Therapy for Acute Lymphoblastic Leukemia: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

CAR T-Cell Therapy for Acute Lymphoblastic Leukemia – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

CAR T-Cell Therapy for Acute Lymphoblastic Leukemia companies' collaborations, Licensing, Acquisition -Deal Value Trends

CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Mid Stage Products (Phase I/II)

Comparative Analysis

AUTO 3: Autolus

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I/ II)

Comparative Analysis

PCAR019: PersonGen Biotherapeutics

Product Description

Research and Development



Product Development Activities  
Drug profiles in the detailed report.....  
Pre-clinical and Discovery Stage Products  
    Comparative Analysis  
    Product Description  
    Research and Development  
    Product Development Activities  
Drug profiles in the detailed report.....  
Inactive Products  
    Comparative Analysis  
CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Key Companies  
CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Key Products  
CAR T-Cell Therapy for Acute Lymphoblastic Leukemia- Unmet Needs  
CAR T-Cell Therapy for Acute Lymphoblastic Leukemia- Market Drivers and Barriers  
CAR T-Cell Therapy for Acute Lymphoblastic Leukemia- Future Perspectives and  
Conclusion  
CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Analyst Views  
CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Key Companies  
Appendix

## List Of Tables

### LIST OF TABLES

Table 1 Total Products for CAR T-Cell Therapy for Acute Lymphoblastic Leukemia

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

## List Of Figures

### LIST OF FIGURES

Figure 1 Total Products for CAR T-Cell Therapy for Acute Lymphoblastic Leukemia

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

## I would like to order

Product name: CAR T-Cell Therapy for Acute Lymphoblastic Leukemia - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/CFFDF2D9A754EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CFFDF2D9A754EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970